Antti VuolantoCEO at Herantis Pharma PlcSpeaker
Profile
CEO Antti Vuolanto, DSc (Tech), started in his current role in July 2022. He joined Herantis Pharma
Plc in February 2018 as COO. Antti has vast experience in financing, partnering, research, development,
and manufacturing of biological drugs. Previously he served as COO at Valo Therapeutics, Executive
Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that merged with
Targovax in 2015. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocessengineering.